专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US5844075A Melanoma antigens and their use in diagnostic and therapeutic methods 失效
公开(公告)号：US5844075A
公开(公告)日：1998-12-01
申请号：US417174
申请日：1995-04-05
申请人： Yutaka Kawakami , Steven A. Rosenberg
发明人： Yutaka Kawakami , Steven A. Rosenberg
IPC分类号： A01K67/027 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/47 , C07K14/82 , C07K16/32 , C12N5/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , G01N33/577 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

12. 发明申请

US20100291677A1 REDUCER OF IMMUNOSUPPRESSION BY TUMOR CELL AND ANTITUMOR AGENT USING THE SAME 审中-公开
标题翻译：使用肿瘤细胞和抗肿瘤药物免疫的免疫抑制剂
公开(公告)号：US20100291677A1
公开(公告)日：2010-11-18
申请号：US12674881
申请日：2008-08-22
申请人： Chie Kudo , Yutaka Kawakami
发明人： Chie Kudo , Yutaka Kawakami
IPC分类号： C12N5/071 , C07K14/47 , C07K16/26
CPC分类号： C07K16/2866 , A61K31/00 , A61K38/1709 , A61K38/1793 , A61K38/195 , A61K2039/505 , C07K14/4702 , C07K16/18 , C07K16/24 , C07K16/30 , C07K2317/73 , C12N5/0693 , C12N15/113 , C12N2310/14 , C12N2501/148 , C12N2502/1114 , C12N2502/1157 , C12N2502/30 , C12N2510/00
摘要： In order to provide a gene expression enhancer for enhancing expression of FoxP3 gene in a cell; a cell differentiation inducer for inducing differentiation of a cell into a regulatory T cell; an immunosuppressor for suppressing immunity and an agent for treating hyperimmune diseases based on the abovementioned actions; an inhibitor of enhancement of gene expression for inhibiting enhancement of expression of FoxP3 gene in a cell; an inhibitor of induction of cell differentiation for inhibiting induction of differentiation of a cell into a regulatory T cell; a reducer of immunosuppression for reducing immunosuppression, a stimulator of tumor immunity and an antitumor agent based on the abovementioned actions; and the like, for example, an agent containing at least one of a cell expressing Snail protein, MCP1 protein, FSTL1 protein, membrane IL-13Ra2 protein or secretory IL-13Ra2 protein, or MCP1 protein, FSTL1 protein or secretory IL-13Ra2 protein, is used as a gene expression enhancer for FoxP3, an inducer of regulatory T cell differentiation, an immunosuppressor or an agent for treating hyperimmune diseases; and an agent containing an anti-MCP1 antibody, an anti-FSTL1 antibody or an anti-IL-13Ra2 antibody is used as an inhibitor of enhancement of FoxP3 gene expression, a reducer of immunosuppression, a stimulator of tumor immunity, an antitumor agent, or the like.
摘要翻译：为了提供用于增强细胞中FoxP3基因表达的基因表达增强子; 用于诱导细胞分化成调节性T细胞的细胞分化诱导物; 用于抑制免疫的免疫抑制剂和基于上述作用的用于治疗超免疫疾病的药剂; 用于抑制细胞中FoxP3基因表达增强的基因表达增强抑制剂; 用于抑制诱导细胞分化成调节性T细胞的细胞分化诱导抑制剂; 基于上述作用的减少免疫抑制的减少剂，免疫抑制的刺激剂和抗肿瘤剂; 例如含有表达Snail蛋白，MCP1蛋白，FSTL1蛋白，膜IL-13Ra2蛋白或分泌型IL-13Ra2蛋白的细胞或MCP1蛋白，FSTL1蛋白或分泌型IL-13Ra2蛋白中的至少一种的药剂用作FoxP3的基因表达增强子，FoxP3是调节性T细胞分化的诱导剂，免疫抑制剂或治疗超免疫疾病的药剂; 使用含有抗MCP1抗体，抗FSTL1抗体或抗IL-13Ra2抗体的药剂作为FoxP3基因表达增强抑制剂，免疫抑制剂的减少剂，肿瘤免疫刺激剂，抗肿瘤剂，或类似物。

13. 发明申请

US20080289055A1 MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS 有权
公开(公告)号：US20080289055A1
公开(公告)日：2008-11-20
申请号：US11932338
申请日：2007-10-31
申请人： Yutaka Kawakami , Steven A. Rosenberg
发明人： Yutaka Kawakami , Steven A. Rosenberg
IPC分类号： A01K67/00 , C12N1/21 , C12N1/19 , C12N15/64
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

14. 发明申请

US20070254844A1 MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS 有权
标题翻译： MELANOMA抗原及其在诊断和治疗方法中的应用
公开(公告)号：US20070254844A1
公开(公告)日：2007-11-01
申请号：US11751233
申请日：2007-05-21
申请人： Yutaka Kawakami , Steven Rosenberg
发明人： Yutaka Kawakami , Steven Rosenberg
IPC分类号： A61K38/03 , A61P35/00
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
摘要翻译：本发明提供编码被称为MART-1的T淋巴细胞识别的黑素瘤抗原的核酸序列。本发明还涉及使用本发明的核酸序列，蛋白质或抗体诊断，评估或预测患有黑素瘤或转移性黑素瘤的哺乳动物的生物测定。本发明还提供衍生自MART-1黑素瘤抗原的免疫原性肽和称为gp100的第二黑素瘤抗原。本发明还提供衍生自MART-1黑素瘤抗原或gp100抗原的免疫原性肽，其已被修饰以增强其免疫原性。所提供的蛋白质和肽可以作为预防或治疗黑素瘤的免疫原或疫苗。

15. 发明授权

US06965017B2 Melanoma antigens and their use in diagnostic and therapeutic methods 有权
标题翻译：黑素瘤抗原及其在诊断和治疗方法中的应用
公开(公告)号：US06965017B2
公开(公告)日：2005-11-15
申请号：US09898860
申请日：2001-07-03
申请人： Yutaka Kawakami , Steven A. Rosenberg
发明人： Yutaka Kawakami , Steven A. Rosenberg
IPC分类号： A01K67/027 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/04 , C07K14/47 , C07K14/82 , C07K16/32 , C12N5/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , G01N33/577 , C07K16/00
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
摘要翻译：本发明提供编码被称为MART-1的T淋巴细胞识别的黑素瘤抗原的核酸序列。本发明还涉及使用本发明的核酸序列，蛋白质或抗体诊断，评估或预测患有黑素瘤或转移性黑素瘤的哺乳动物的生物测定。本发明还提供衍生自MART-1黑素瘤抗原的免疫原性肽和称为gp100的第二黑素瘤抗原。本发明还提供衍生自MART-1黑素瘤抗原或gp100抗原的免疫原性肽，其已被修饰以增强其免疫原性。所提供的蛋白质和肽可以作为预防或治疗黑素瘤的免疫原或疫苗。

16. 发明授权

US06537560B1 Melanoma antigens and their use in diagnostic and therapeutic methods 失效
公开(公告)号：US06537560B1
公开(公告)日：2003-03-25
申请号：US09073138
申请日：1998-05-05
申请人： Yutaka Kawakami , Steven A. Rosenberg
发明人： Yutaka Kawakami , Steven A. Rosenberg
IPC分类号： A61K3900
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

17. 发明授权

US5874560A Melanoma antigens and their use in diagnostic and therapeutic methods 失效
公开(公告)号：US5874560A
公开(公告)日：1999-02-23
申请号：US231565
申请日：1994-04-22
申请人： Yutaka Kawakami , Steven A. Rosenberg
发明人： Yutaka Kawakami , Steven A. Rosenberg
IPC分类号： A01K67/027 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/47 , C07K14/82 , C07K16/32 , C12N5/10 , C12N15/09 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , G01N33/577 , C07H21/02 , C07H21/04
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

18. 发明授权

US08323659B2 Method for diagnosing and/or treating tumor 有权
标题翻译：诊断和/或治疗肿瘤的方法
公开(公告)号：US08323659B2
公开(公告)日：2012-12-04
申请号：US13119645
申请日：2009-09-11
申请人： Chie Kudo , Yutaka Kawakami
发明人： Chie Kudo , Yutaka Kawakami
IPC分类号： A61K39/21 , A61K39/38 , A61K39/00 , A61K39/12 , A61K38/00 , A61K38/04 , C12N5/00 , C12N5/02 , C12N15/00
CPC分类号： A61K39/21 , A61K31/713 , A61K39/00 , A61K39/12 , A61K47/6901 , A61K2039/515 , A61K2039/5154 , A61K2039/53 , C07K14/005 , C12N15/113 , C12N15/1132 , C12N2310/14 , C12N2740/10022 , C12N2740/10034 , C12Q1/6886 , C12Q2600/158
摘要： An object of the present invention is to provide methods for diagnosing and/or treating tumors using HERV-H env gene or HERV-H env Env protein. Specifically, tumors are diagnosed by detecting expression of HERV-H env gene; and agents for detecting the expression are used as diagnosing agents. Further, tumors are treated by inhibiting function of HERV-H env gene; and agents for inhibiting the function are used as antitumor agents. Furthermore, tumors are treated by administering a peptide having a certain sequence of HERV-H Env protein and the like; and the peptide is used as a cancer vaccine.
摘要翻译：本发明的目的是提供使用HERV-H env基因或HERV-H env Env蛋白来诊断和/或治疗肿瘤的方法。具体地，通过检测HERV-H env基因的表达来诊断肿瘤; 用于检测该表达的试剂用作诊断试剂。此外，通过抑制HERV-H env基因的功能来治疗肿瘤; 并且用于抑制该功能的药剂用作抗肿瘤剂。此外，通过施用具有一定序列的HERV-H Env蛋白等的肽来治疗肿瘤; 并且该肽用作癌症疫苗。

19. 发明申请

US20110217326A1 METHOD FOR DIAGNOSING AND/OR TREATING TUMOR 有权
标题翻译：用于诊断和/或治疗肿瘤的方法
公开(公告)号：US20110217326A1
公开(公告)日：2011-09-08
申请号：US13119645
申请日：2009-09-11
申请人： Chie Kudo , Yutaka Kawakami
发明人： Chie Kudo , Yutaka Kawakami
IPC分类号： A61K39/00 , C12N5/078 , C12Q1/68 , C07H21/02 , A61K31/7088 , C07K7/06 , C12N5/0783 , A61K48/00 , A61K35/12 , A61P35/00 , A61P37/04
CPC分类号： A61K39/21 , A61K31/713 , A61K39/00 , A61K39/12 , A61K47/6901 , A61K2039/515 , A61K2039/5154 , A61K2039/53 , C07K14/005 , C12N15/113 , C12N15/1132 , C12N2310/14 , C12N2740/10022 , C12N2740/10034 , C12Q1/6886 , C12Q2600/158
摘要： An object of the present invention is to provide methods for diagnosing and/or treating tumors using HERV-H env gene or HERV-H env protein. Specifically, tumors are diagnosed by detecting expression of HERV-H env gene; and agents for detecting the expression are used as diagnosing agents. Further, tumors are treated by inhibiting function of HERV-H env gene; and agents for inhibiting the function are used as antitumor agents. Furthermore, tumors are treated by administering a peptide having a certain sequence of HERV-H env protein and the like; and the peptide is used as a cancer vaccine.
摘要翻译：本发明的目的是提供使用HERV-H env基因或HERV-H env蛋白来诊断和/或治疗肿瘤的方法。具体地，通过检测HERV-H env基因的表达来诊断肿瘤; 用于检测该表达的试剂用作诊断试剂。此外，通过抑制HERV-H env基因的功能来治疗肿瘤; 并且用于抑制该功能的药剂用作抗肿瘤剂。此外，通过施用具有一定序列的HERV-H env蛋白等的肽来治疗肿瘤; 并且该肽用作癌症疫苗。

20. 发明授权

US07612044B2 Melanoma antigens and their use in diagnostic and therapeutic methods 有权
标题翻译：黑素瘤抗原及其在诊断和治疗方法中的应用
公开(公告)号：US07612044B2
公开(公告)日：2009-11-03
申请号：US11751233
申请日：2007-05-21
申请人： Yutaka Kawakami , Steven A. Rosenberg
发明人： Yutaka Kawakami , Steven A. Rosenberg
IPC分类号： A61K38/00 , C07K5/00
CPC分类号： C07K14/47 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5256 , A61K2039/53 , C07K14/4748 , G01N33/5743
摘要： The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.
摘要翻译：本发明提供编码被称为MART-1的T淋巴细胞识别的黑素瘤抗原的核酸序列。本发明还涉及使用本发明的核酸序列，蛋白质或抗体诊断，评估或预测患有黑素瘤或转移性黑素瘤的哺乳动物的生物测定。本发明还提供衍生自MART-1黑素瘤抗原的免疫原性肽和称为gp100的第二黑素瘤抗原。本发明还提供衍生自MART-1黑素瘤抗原或gp100抗原的免疫原性肽，其已被修饰以增强其免疫原性。所提供的蛋白质和肽可以作为预防或治疗黑素瘤的免疫原或疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式